Ronald Blue Trust, Inc. Apellis Pharmaceuticals, Inc. Transaction History
Ronald Blue Trust, Inc.
- $7.68 Billion
- Q1 2025
A detailed history of Ronald Blue Trust, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 305 shares of APLS stock, worth $5,859. This represents 0.0% of its overall portfolio holdings.
Number of Shares
305
Previous 332
8.13%
Holding current value
$5,859
Previous $10,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding APLS
# of Institutions
296Shares Held
111MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$235 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$228 Million17.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$193 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$185 Million0.02% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$111 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.11B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...